Short-term effects of air pollution and weather on physical activity in patients with chronic obstructive pulmonary disease (COPD).

Air pollution COPD Exposure Physical activity levels Short-term Weather

Journal

Environmental research
ISSN: 1096-0953
Titre abrégé: Environ Res
Pays: Netherlands
ID NLM: 0147621

Informations de publication

Date de publication:
16 Jan 2024
Historique:
received: 08 11 2023
revised: 27 12 2023
accepted: 11 01 2024
medline: 19 1 2024
pubmed: 19 1 2024
entrez: 18 1 2024
Statut: aheadofprint

Résumé

Patients with chronic obstructive pulmonary disease (COPD) accumulate low levels of physical activity. How environmental factors affect their physical activity in the short-term is uncertain. to assess the short-term effects of air pollution and weather on physical activity levels in COPD patients. This multi-center panel study assessed 408 COPD patients from Catalonia (Spain). Daily physical activity (i.e., steps, time in moderate-to-vigorous physical activity (MVPA), locomotion intensity, and sedentary time) was recorded in two 7-day periods, one year apart, using the Dynaport MoveMonitor. Air pollution (nitrogen dioxide (NO Patients (85% male) were on average (mean ± SD) 68 ± 9 years old with a post-bronchodilator forced expiratory volume in 1 s (FEV Air pollution affects the amount and intensity of physical activity performed on the following days in COPD patients, whereas weather affects the amount of physical activity performed on the same day.

Identifiants

pubmed: 38237751
pii: S0013-9351(24)00099-9
doi: 10.1016/j.envres.2024.118195
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118195

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Robert Rodriguez-Roisin reports a relationship with Chiesi España SA that includes: consulting or advisory and speaking and lecture fees. Judith Garcia-Aymerich reports a relationship with Esteve that includes: speaking and lecture fees. Judith Garcia-Aymerich reports a relationship with Chiesi España SA that includes: speaking and lecture fees. Judith Garcia-Aymerich reports a relationship with AstraZeneca Pharmaceuticals LP that includes: speaking and lecture fees. Judith Garcia-Aymerich reports a relationship with Menarini Laboratories that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Alícia Josa-Culleré (A)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.

Xavier Basagaña (X)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.

Sarah Koch (S)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.

Ane Arbillaga-Etxarri (A)

Deusto Physical TherapIker, Physical Therapy Department, Faculty of Health Sciences, University of Deusto, Donostia-San Sebastián, Spain.

Eva Balcells (E)

Universitat Pompeu Fabra (UPF), Barcelona, Spain; Respiratory Medicine Department, Hospital del Mar, Barcelona, Spain; CIBER Respiratory Disease (CIBERES), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain; Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Magda Bosch de Basea (M)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.

Nuria Celorrio (N)

Clinical pneumologist, Department of Respiratory Medicine Hospital de Viladecans, Barcelona, Spain.

Maria Foraster (M)

PHAGEX Research Group, Blanquerna School of Health Science, Universitat Ramon Llull (URL), Barcelona, Spain.

Robert Rodriguez-Roisin (R)

CIBER Respiratory Disease (CIBERES), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

Alicia Marin (A)

Department of Respiratory Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Germans Trias i Pujol Research Institute - IGTP, Badalona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.

Gabriela P Peralta (GP)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.

Diego A Rodríguez-Chiaradia (DA)

Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Respiratory Disease (CIBERES), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain; Department of Pulmonary Medicine, Hospital del Mar, Spain.

Pere Simonet (P)

EAP Viladecans-2. Gerencia Metropolitana Sud, ICS, Spain.

Pere Torán-Monserrat (P)

Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Mataró, Spain; Multidisciplinary Research Group in Health and Society (GREMSAS) (2021 SGR 01484), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Spain; Department of Medicine, Faculty of Medicine, Universitat de Girona, 17001 Girona, Spain.

Pere Vall-Casas (P)

Universitat Internacional de Catalunya, Barcelona, Spain.

Judith Garcia-Aymerich (J)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain. Electronic address: judith.garcia@isglobal.org.

Classifications MeSH